On September 7, 2021 Viracta Therapeutics, Inc. (NASDAQ: VIRX), a precision oncology company targeting virus-associated malignancies, reported that company management will present and be available for virtual one-on-one meetings at the H.C. Wainwright 23rd Annual Global Investment Conference, September 13 – 15, 2021, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, September 20 – 23, 2021, and the 2021 Cantor Virtual Global Healthcare Conference, September 27 – 30, 2021 (Press release, Viracta Therapeutics, SEP 7, 2021, View Source [SID1234587351]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the presentations can be found below.

H.C. Wainwright 23rd Annual Global Investment Conference

Presentation Date:

Corporate presentation will be available on-demand to conference
registrants starting at 7:00 AM ET on September 13, 2021

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Presentation Date:

September 21, 2021

Presentation Time:

4:35 PM ET

Format:

Corporate presentation

Webcast Link:

View Source

2021 Cantor Virtual Global Healthcare Conference

Presentation Date:

September 30, 2021

Presentation Time:

8:40 AM ET

Format:

Corporate presentation

A replay of the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit presentation will be available on the "Events and Webcasts" section of the Viracta website at View Source

On September 7, 2021 Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, reported that it will be presenting at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference (Press release, Aethlon Medical, SEP 7, 2021, https://www.prnewswire.com/news-releases/aethlon-medical-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-301370027.html [SID1234587350]). The conference is being held virtually from September 13-15, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Charles J. Fisher, M.D., Chief Executive Officer, will present an overview of Aethlon Medical the conference. The presentation will be available on-demand beginning Monday, September 13 at 7:00 AM EDT at the link below and will be archived for 90 days. It will also be available on the Aethlon website. In addition to the overview presentation, Dr. Fisher will be hosting virtual one-on-one meetings at the conference on Monday, September 13.

Event: H.C. Wainwright 23rd Annual Global Investment Conference (Virtual Conference)

Date: September 13, 2021

Time: 7:00 AM EDT

Location: Virtual Conference

Company Webcasting Link: View Source

On September 7, 2021 Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported the signing of a memorandum of understanding with immunotherapy company Eutilogics, Inc., the wholly owned subsidiary of clinical stage Korean company, Eutilex Co., Ltd., based on exploring synergies between technologies of both Companies (Press release, Therapeutics Solutions International, SEP 7, 2021, View Source [SID1234587349]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Eutilex has developed an autologous immunotherapy for tumors which unleash the endogenous ability of T cells to selectively kill tumor cells, even in solid tumors, which will be commercially developed in the US by Eutilogics. As the discoverer of CD137 (4-1BB) and AITR receptors, Eutilogics CEO, Dr. Byoung S. Kwon, is an internationally renowned expert of the immune system, and TAST is a globally competitive targeted cell therapy treatment, which is the result of the validation of decades of research and development.

Therapeutic Solutions International has recently filed an Investigational New Drug application for its StemVacs-V tumor-angiogenesis targeting immunotherapy in breast cancer. StemVacs-V has been demonstrated to induce immune responses to kill blood vessels that feed tumors. StemVacs-V has demonstrated superior tumor inhibition in comparison to other blood vessel targeting immunotherapies in animal models.

"Having collaborated with scientists from Therapeutic Solutions International for several years, we are eager to take our work to the next level through this memorandum of understanding formalizing our collaboration," said Dr. Byoung S. Kwon. "Given that Therapeutic Solutions International has synergistic expertise in cell therapy, we hope to advance more treatment options for patients, much faster."

"Eutilex has been a pioneer in creating novel immunotherapies that leverage the unique molecule 4.1 BB, which is one of the keys in creating an optimized T cell response against tumors. We hope to leverage this technology to kill tumor blood vessels, which appear to be more sensitive towards immunologically based targeting," said Timothy Dixon, President and CEO of Therapeutic Solutions International.

On September 7, 2021 DURECT Corporation (Nasdaq: DRRX) reported that James E. Brown, President, CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer and Dr. WeiQi Lin, Executive Vice President of R&D will be participating in a fireside chat hosted by Ed Arce of H.C. Wainwright, at the H.C. Wainwright 23rd Annual Global Investment Conference (Press release, DURECT, SEP 7, 2021, https://www.prnewswire.com/news-releases/durect-corporation-fireside-chat-at-the-hc-wainwright-annual-global-investment-conference-301370065.html [SID1234587348]). A recording of the fireside chat will be available on-demand starting at 7:00 A.M. Eastern Standard Time on September 13, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details are as follows:

H.C. Wainwright 23rd Annual Global Investment Conference

Date:

September 13-15, 2021

Time:

Recording will be available on-demand starting at 7:00 A.M. (ET) on September 13, 2021

Format:

Fireside chat hosted by Ed Arce

Webcast:

View Source

The webcast link of the presentation will also be available by accessing DURECT’s homepage at www.durect.com and clicking on "Event Calendar" under the "Investors" section.

Management will also be available for virtual 1×1 meetings during the conference. If you would like to request a meeting, please contact [email protected].

On September 7, 2021 Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, reported it will be participating in two upcoming virtual investor conferences (Press release, Lantern Pharma, SEP 7, 2021, View Source [SID1234587347]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Colliers Institutional Investor Conference
Panna Sharma, President & CEO of Lantern Pharma, will be hosting one-on-one meetings at the 2021 Colliers Institutional investor conference being held virtually September 9-10, 2021. Investors interested in arranging a meeting should contact their Collier sales representative.

H.C. Wainwright 23rd Annual Global Investment Conference
Mr. Sharma will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually between September 13-15, 2021. Lantern’s presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 13, 2021, at 7:00 AM Eastern Time. The webcast can be accessed here and on the investor relations section of Lantern’s website at View Source Management will also be participating in one-on-one meetings with qualified members of the investor community throughout the conference.